Study of a new drug with chemotherapy for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests an investigational drug called QL1706 combined with chemotherapy, given after standard chemoradiation, for people with limited-stage small cell lung cancer. The goal is to see if this combination helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have limited-stage small cell lung cancer confirmed by biopsy.
- You have at least one tumor that can be measured on a scan.
- You are in good enough health to perform daily activities (ECOG score 0 or 1).
- Your lung function test (FEV1) is above 1.0 liter.
- You have not had any prior systemic cancer therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial combines radiation therapy with chemotherapy and an immunotherapy drug to treat limited-stage small cell lung cancer. The goal is to see if this approach helps people live longer and delays the cancer from coming back.
This trial tests combining standard chemotherapy with radiation (chemoradiotherapy) plus two additional drugs, toripalimab and surufatinib, for people with limited-stage small cell lung cancer. The goal is to see if this combination improves outcomes.
This Phase 2 study tests whether adding a PD-L1 antibody to chemotherapy helps people with newly diagnosed limited-stage small-cell lung cancer live longer and control the cancer better. It may benefit patients who have not had any prior cancer treatment for SCLC and can meet health and lab requirements.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This study tests a new combination of two drugs (QL1706 and anlotinib) for people with advanced small cell lung cancer or squamous cell lung cancer who have already tried at least two earlier treatments. The goal is to see if this combination can help control the cancer when other options have stopped working.
Hear when a new Limited-stage Small Cell Lung Cancer (LS-SCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.